Cipla says top 50 drugs in development could bring in $30B

Indian drugmaker Cipla said it currently has 200 drugs in development and that the top 50 of those drugs have the potential to earn the company more than $30 billion.

The Mumbai-based company also said it plans to expand its North American market share to 25% by 2020 and plans to devote more resources to R&D for that specific market. It also plans to seek more generics approvals there, according to a report in the Business Standard.

The company said in an investor presentation that it had "strong" development and filing potential with respiratory and HIV candidates and said its top 50 drugs under development are in sectors such as respiratory, oncology, antiretroviral and others with "20 in solid oral form of delivery, 13 injectables, 12 inhalation and five in other delivery forms," the report said.

Cipla Managing Director Subhanu Saxena

The company told investors it planned to file from 10 to 15 abbreviated new drug applications (ANDAs) each year and said it would "transition from a pure B2B to Direct plus B2B model in the U.S.," with its HIV and oncology treatments.

Drugs such as esomeprazole, Dymista nasal spray, budesonide respules, escitalopram and finasteride will feature in its partnerships; the company also plans to release the "product pipeline" of Invagen as part of its post-$500 million acquisition activities from its takeover of InvaGen Pharmaceuticals.

As FiercePharmaAsia reported earlier this month, the company's moves on the North American market come after it reshuffled top management and created a 6-member management council to keep up with rivals like Sun Pharmaceuticals and Dr. Reddy's ($RDY).

- here's the report from the Business Standard

Suggested Articles

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

Hoping to expand its hospital portfolio in Japan, the Novartis generics unit is buying Aspen Pharmacare's operations there for up to €400 million.

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.